Illumina, Inc. (NASDAQ:ILMN) Shares Sold by Banque Pictet & Cie SA

Banque Pictet & Cie SA trimmed its holdings in shares of Illumina, Inc. (NASDAQ:ILMN - Free Report) by 32.0% during the 4th quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 56,470 shares of the life sciences company's stock after selling 26,575 shares during the quarter. Banque Pictet & Cie SA's holdings in Illumina were worth $7,546,000 as of its most recent SEC filing.

A number of other large investors also recently bought and sold shares of the business. WCM Investment Management LLC increased its holdings in shares of Illumina by 26.6% in the 4th quarter. WCM Investment Management LLC now owns 4,129,855 shares of the life sciences company's stock valued at $551,625,000 after acquiring an additional 867,673 shares during the period. Geode Capital Management LLC boosted its holdings in shares of Illumina by 1.8% in the 3rd quarter. Geode Capital Management LLC now owns 2,727,827 shares of the life sciences company's stock valued at $354,933,000 after buying an additional 48,018 shares in the last quarter. Primecap Management Co. CA grew its position in shares of Illumina by 3.6% in the 3rd quarter. Primecap Management Co. CA now owns 2,516,359 shares of the life sciences company's stock worth $328,158,000 after buying an additional 87,599 shares during the last quarter. Janus Henderson Group PLC raised its stake in shares of Illumina by 40.5% during the 3rd quarter. Janus Henderson Group PLC now owns 2,168,057 shares of the life sciences company's stock worth $282,735,000 after acquiring an additional 625,245 shares in the last quarter. Finally, UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC lifted its position in Illumina by 4.5% during the third quarter. UBS AM a distinct business unit of UBS ASSET MANAGEMENT AMERICAS LLC now owns 1,260,137 shares of the life sciences company's stock valued at $164,334,000 after acquiring an additional 54,319 shares during the last quarter. Institutional investors own 89.42% of the company's stock.

Illumina Stock Performance

ILMN stock traded up $0.81 during trading on Tuesday, hitting $101.05. 2,919,076 shares of the company traded hands, compared to its average volume of 2,421,951. The company has a debt-to-equity ratio of 0.94, a current ratio of 2.43 and a quick ratio of 1.85. Illumina, Inc. has a 1 year low of $99.33 and a 1 year high of $156.66. The stock's 50-day simple moving average is $131.80 and its 200 day simple moving average is $134.75. The company has a market cap of $16.03 billion, a PE ratio of -13.16 and a beta of 1.10.

Illumina (NASDAQ:ILMN - Get Free Report) last posted its earnings results on Thursday, February 6th. The life sciences company reported $0.86 earnings per share (EPS) for the quarter, missing the consensus estimate of $0.92 by ($0.06). Illumina had a negative net margin of 27.95% and a positive return on equity of 12.59%. On average, equities analysts expect that Illumina, Inc. will post 4.42 earnings per share for the current fiscal year.

Analyst Upgrades and Downgrades

A number of analysts have recently weighed in on ILMN shares. JPMorgan Chase & Co. raised their price objective on Illumina from $125.00 to $140.00 and gave the stock a "neutral" rating in a research report on Tuesday, November 5th. Piper Sandler raised their price target on Illumina from $185.00 to $190.00 and gave the stock an "overweight" rating in a report on Monday, February 10th. Morgan Stanley cut their price objective on shares of Illumina from $150.00 to $136.00 and set an "equal weight" rating on the stock in a report on Tuesday, February 11th. Robert W. Baird increased their price objective on shares of Illumina from $124.00 to $139.00 and gave the company a "neutral" rating in a research report on Wednesday, November 6th. Finally, Guggenheim dropped their target price on shares of Illumina from $170.00 to $150.00 and set a "buy" rating on the stock in a research report on Friday, February 7th. One equities research analyst has rated the stock with a sell rating, eight have given a hold rating, eleven have assigned a buy rating and two have given a strong buy rating to the company. According to data from MarketBeat, Illumina has an average rating of "Moderate Buy" and a consensus target price of $159.45.

Illumina Company Profile

Illumina, Inc offers sequencing- and array-based solutions for genetic and genomic analysis in the United States, Singapore, the United Kingdom, and internationally. It operates through Core Illumina and GRAIL segments. The company offers sequencing and array-based instruments and consumables, which include reagents, flow cells, and library preparation; whole-genome sequencing kits, which sequence entire genomes of various size and complexity; and targeted resequencing kits, which sequence exomes, specific genes, and RNA or other genomic regions of interest.